AKAP4 and non-small cell lung carcinoma: To further confirm the potential utility of AKAP4 and GAGE4 as NSCLC biomarkers, we analyzed an additional cohort of 141 NSCLC patients and 35 control patients with benign lung diseases which did not include any of the discovery set samples (Table 1).